- Home
- EWTX
as 12-20-2024 4:00pm EST
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | BOULDER |
| Market Cap: | 2.7B | IPO Year: | 2021 |
| Target Price: | $44.83 | AVG Volume (30 days): | 896.5K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.00 - $38.12 | Next Earning Date: | 02-20-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Edgewise Therapeutics Inc. News
EWTX Breaking Stock News: Dive into EWTX Ticker-Specific Updates for Smart Investing
Zacks
4 days ago
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains
Zacks
5 days ago
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study
Benzinga
6 days ago
Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease
MT Newswires
6 days ago
Sector Update: Health Care Stocks Mixed Pre-Bell Monday
MT Newswires
6 days ago
Sector Update: Health Care
MT Newswires
6 days ago
Edgewise's Phase 2 Trial of Sevasemten to Treat Becker Muscular Dystrophy Meets Primary Endpoint; Shares Up 22% Pre-Bell
BioPharma Dive
6 days ago
Edgewise weighs fast approval path for muscular dystrophy drug
Business Wire
6 days ago
Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)
Compare EWTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EWTX Edgewise Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.